• Dignitana AB
    Traktorgränden 3, SE - 226 60 Lund, Sweden
    +46 46 163090
  • Quotes

    I appreciate the entrepreneurial spirit of Dignitana and I see many similarities in this company compared to where CellaVision was when I joined that company. Dignitana is a growing company with tremendous potential – it has global reach, an excellent product, and a solid foundation. I am excited about the opportunity and look forward to continuing the good work of the company to improve well-being and the lives of cancer patients.
    Magnus Blixt
    The strategic expansion of the company is our top priority. We are well-positioned to take advantage of the opportunities before us in the critical US market and around the globe, and the financial and operational experience that Magnus Blixt brings will be a tremendous asset to the Company.
    Klas Arildsson, Chairman of the Board, Dignitana AB
    I firmly believe that we have made the right choices and realigned our organization to take the next step towards attaining our long-awaited goal of cash flow positivity.
    William Cronin, CEO Dignitana AB
    Medicare coverage is critical to our overall reimbursement efforts and will undoubtedly increase utilization with existing customers and drive demand for DigniCap at new facilities.
    William Cronin, Dignitana CEO
    This decision ensures that thousands of cancer patients will now have access to life-changing scalp cooling therapy that was previously financially out of reach. It is a major milestone for Dignitana and for so many in the cancer treatment community who have worked tirelessly to make scalp cooling standard of care.
    William Cronin, Dignitana CEO
    Keeping my hair helped me keep a part of myself that felt strong and centered. It was a blessing in a very difficult time.
    Audra Byrne
    When cancer happened to me, I didn’t know what to do or where to turn. I’ll never forget that feeling, and I want to be there for other women who might be feeling the same.
    Melanie Waxler
    Putting patients first is a priority for Dignitana, and we are honored to recognize these inspirational patient stories through the DigniCap Dignitary program.
    William Cronin, Chief Executive Officer of Dignitana
    My hair is so much a part of who I am,” Agostino said. “This treatment can help so many people. It helped me keep a positive mindset the whole time, and there’s no way that would have been possible for me without keeping my hair.
    Lori Agostino
    Dignitana continues our growth trajectory, and the second period of the year provides solid evidence of the progress we are making.
    William Cronin, CEO Dignitana AB
    As supplier we strive to provide the best quality devices, and we are very excited to introduce the next generation DigniCap Delta system to the oncology sector in Benelux. Infection prevention is a priority for our customers, and DigniCap effectively addresses this with their unique single patient cap system.
    Bob Geerts, CEO and Founder of B&Co Group
    When the AMA announced the CPT codes for scalp cooling last fall, we initiated a plan to do our part to help the oncology community establish appropriate reimbursement. JDL Access and JD Lymon are the ideal partners to help us achieve that.
    William Cronin, Dignitana CEO
    Our relentless commitment to patient success is the driving force behind everything we do. By maintaining this focus and making scalp cooling a standard of care, I am confident that we will meet our long-term financial goals.
    William Cronin, CEO Dignitana AB
    The success of the DigniCap clinical evaluation in Australia has been quite impressive and we are eager to make this technology available to a wider audience. We are committed to providing best in class care for our patients and our partnership with Dignitana provides significant value to our medical oncology patients.
    Alyson Tiedeman, GenesisCare U.S. Regional Leader East Florida
    GenesisCare is known for exemplary patient care and we are honored to have them on our growing list of DigniCap providers around the globe. Quality of life is extremely important for cancer patients. As awareness of the efficacy of DigniCap increases, demand for this life-changing treatment is growing as well.
    William Cronin, Dignitana CEO
    The Company’s agility and adaptability have helped Dignitana to not just survive during the pandemic, but also to thrive as we strategically move toward attaining our operational and financial goals.
    William Cronin, CEO Dignitana AB
    Patients from around the world come to Mammazentrum for cutting-edge cancer care. DigniCap is an important part of our integrative approach, helping to preserve a patient’s privacy and self-esteem during a very difficult time.
    Prof. Dr. Christian Schem, Partner and Associate Director of Mammazentrum Hamburg
    Mammazentrum is a recognized leader in cancer care and has been a valued Dignitana customer for many years. We are excited to enhance their scalp cooling program with our latest technology. Clinicians in Europe and around the world are seeing first-hand the advantages offered by DigniCap Delta, and the successful outcomes at Mammazentrum are a prime example of this.
    William Cronin, Dignitana CEO
    At GenesisCare we believe in a holistic approach to cancer care which considers both the physical and emotional needs of our patients. We share Dignitana’s commitment to minimizing the emotional burdens associated with chemotherapy and supporting the psychological health of cancer patients.
    Ian Maytom, GenesisCare General Manager for Medical Oncology in Australia
    With this partnership DigniCap is accessible to thousands more patients who would otherwise face the prospect of losing their hair during chemotherapy. GenesisCare truly is a global leader in oncology and we are thrilled to be working with their experienced and innovative team who share our commitment of putting patients first.
    William Cronin, Dignitana CEO
    Demand for this important therapy is growing and together we will make scalp cooling a standard in modern cancer care. There is no doubt that scalp cooling is now something that cancer patients want and need to improve their quality of life at a very difficult time.
    Darren Banks, Managing Director of Aurora BioScience
    City of Hope is known for clinical excellence and their commitment to patient care. This expansion has been driven by patient demand in Southern California and the success that patients have with DigniCap. We are thrilled that more patients will now have access this life-changing treatment as we move even closer to scalp cooling becoming a standard of care.
    William Cronin, Dignitana CEO
    This partnership with Dignitana enables us to improve the patient experience, Our physicians are committed to providing exceptional cancer care. By being able to offer the DigniCap to patients undergoing chemotherapy, we’ll be helping to diminish the added emotional burden from hair loss.
    AON CEO Brad Prechtl, MBA
    AON provides a unique model of physician-led community oncology that aligns well with our organizational goals, Physicians know that hair loss is a significant quality of life issue and they want to provide DigniCap for their patients. This master contract expedites the administrative process so that more patients can access this life-changing therapy.
    Dignitana CEO William Cronin
    As one of India’s fastest growing healthcare companies, MedPhy Technologies is known for providing scientifically proven, safe, and clinically effective medical technology to the country’s most trusted health facilities. It is a privilege to partner with MedPhy to bring DigniCap to India.
    William Cronin, Chief Executive Officer of Dignitana AB.
    The preservation of dignity is critically important to any patient. DigniCap addresses one of the most devastating side effects of chemotherapy, preserving a patient’s dignity at a very vulnerable time. The integration of scalp cooling into comprehensive cancer care in India will play an especially important role in improving well-being among the country’s at-risk patient populations.
    Manojkumar Patil, Director, MedPhy Technologies Pvt. Ltd.
    Susan G. Komen remains committed to the fight against breast cancer, taking every step we can toward our mission of saving lives and supporting those affected by breast cancer. We are so grateful for supporters like Dignitana and look forward to seeing the impact our partnership will make.
    Carrie Stovall, Vice President, Fundraising and Events at Susan G. Komen
    “As the world’s leading nonprofit breast cancer organization, Susan G. Komen launched a movement that has made a worldwide impact in the fight against breast cancer. We are honored to support Susan G. Komen and the important work they do from the community level up.
    William Cronin, CEO of Dignitana
    DigniCap Delta changes everything about the way scalp cooling is done today. Australia is a very important market for us and, as scalp cooling has become a standard of care for patients here, the Delta device will enable our partner sites to offer this valuable therapy option to more patients and much more efficiently.
    William Cronin, CEO of Dignitana
    Clinicians want to help patients maintain a level of privacy and control that is often lost after diagnosis. Helping cancer care teams address quality of life is an essential component of what we do every single day. Our DigniCap Dignitaries are just one more way we provide patients with a highly personalized level of support and care.
    William Cronin, CEO Dignitana AB
    Identity, privacy and confidence became important and very personal concerns when I was diagnosed with cancer and put on a chemotherapy regimen. I’m incredibly honored by this opportunity to help others who I’m sure will have tons of questions, just as I did. To have someone who can help you know what to expect is so important. I can’t wait to connect with other cancer patients looking to keep their hair during chemo.
    Sharon Yapoujian, DigniCap Dignitary
    The technological advances engineered into the new DigniCap Delta bring scalp cooling therapy to a whole new level, This streamlined model offers a new gold standard in patient comfort, flexibility and precision fit and is designed for ease of use and efficiency by clinicians.
    William Cronin, CEO Dignitana AB
    As the leading innovator in scalp cooling technology we know first-hand the importance of knowledge, early diagnoses and treatment. We welcome initiatives that highlight the quest for supportive cancer care and enhance quality of life options.
    William Cronin, CEO Dignitana AB
    We are pleased that this approval comes at a time when both awareness of and demand for scalp cooling are rapidly increasing. The clearance of Delta now provides a clear pathway for growth in the important U.S. market and beyond. It is the biggest step yet in the evolution of Dignitana and is the result of a tremendous effort from our staff, partner sites, regulatory team and contract manufacturer.
    William Cronin
    DigniCap Delta changes everything about the way scalp cooling is done today. In the value-based U.S. health care system providers tell us they want to improve the clinical process, reduce nursing intervention and optimize patient outcomes. This new device, developed along with our partner sites, allows them to accomplish all three of these objectives. We are thrilled to offer patients and clinicians this state-of-the-art advancement in cancer care.
    William Cronin
    Dignitana is moving forward with positive momentum. We are confident that the new system will provide clear benefits to hospitals and patients and we look forward to accelerated growth with the launch of this new system in the first half of 2019.
    William Cronin, Chief Executive Officer
    This is a very important first step in our commitment to bring DigniCap to the Asian market in conjunction with our distribution partner Konica Minolta. As of yet there is no data from a clinical study of scalp cooling with an exclusively Asian population. Beijing Cancer Hospital is a leading cancer treatment facility in Asia and we are eager to work with them in this milestone study.
    William Cronin, CEO Dignitana AB
    The results we posted this quarter represent a very important milestone for Dignitana. Quarterly revenue for the company reached 9,022 TSEK. With the organizational restructuring we have implemented, the company is close to reaching a breakeven point in regard to our costs for continuing operations.
    - William Cronin, CEO, Dignitana AB
    As Dignitana now moves into a new chapter, the broad and varied expertise of the proposed slate of Thomas Kelly, Ingrid Atteryd Heiman and Mikael Wahlgren will be a tremendous asset to our continued growth and development.
    William Cronin, CEO Dignitana AB
    We hope this expanded FDA clearance will be welcome news for thousands of Americans diagnosed with solid tumors each year.
    Bill Cronin, CEO Dignitana Inc
    The new decision by the FDA means that our potential market in the US is more than tripled.
    Johan Ericsson
    “The CHILL Registry is an incredible platform that will allow us to track progress and connect with physicians around the world to ensure that we can continue to deliver the most effective scalp cooling treatments available.”
    Johan Ericsson, CEO Dignitana AB
    “Dignitana is keen to align with support groups in the area to facilitate awareness and access to DigniCap treatments”
    William Cronin, Chief Executive Officer of Dignitana, Inc
    Mario Lacouture, MD, Director of the Oncodermatology Program at Memorial Sloan Kettering
    Scalp cooling is clinically proven and can be an important tool for many women in treatment for breast cancer.
    Mario Lacouture, MD, Director of the Oncodermatology Program at Memorial Sloan Kettering
    As a world leader in comprehensive cancer care, we are proud to be able to offer our patients across the New York metro area this new FDA-cleared advancement that addresses one of the most distressing and most visible side effects of chemotherapy.
    William Cronin, Chief Executive Officer of Dignitana, Inc.
    We have just passed the one-year anniversary of clearance by the FDA for DigniCap® in the U.S., and we are proud to add Memorial Sloan Kettering, one of the top comprehensive cancer centers in the U.S., to the growing number of facilities that are providing this treatment option to patients on a large scale.
    William Cronin, Chief Executive Officer of Dignitana, Inc.
    Bringing the DigniCap® system to MSK is an important milestone for Dignitana.
    We are pleased with the consistent strong growth we are experiencing in the U.S. since FDA clearance nine months ago. The DigniCap system is being included as an integral part of the treatments offered by national leaders in comprehensive breast health services in the U.S. Up to date, forty-seven DigniCap scalp-cooling systems have been ordered for installation by US customers.
    Jan Richardsson, Chief Executive Officer of Dignitana
    We are very excited that DigniCap® is being so well-received in the U.S., and that we’ve been able to quickly and effectively fulfil product requests. From the New York Metropolitan area to communities throughout the midwest, the south, and California, it is clear that DigniCap is filling an important need in quality of life cancer care and medical centers are eagerly promoting its addition to their cancer services.
    Jan Richardsson, Chief Executive Officer of Dignitana
    This FDA clearance means that finally, breast cancer patients in the U.S. will have access to a convenient, safe and scientifically proven option for reducing chemotherapy-induced hair loss.
    Jan Richardsson, CEO Dignitana AB
    Pick a time period -
    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top